Plasma Dihydroceramides Are Diabetes Susceptibility Biomarker Candidates in Mice and Humans
Open Access
- 1 February 2017
- journal article
- Published by Elsevier in Cell Reports
- Vol. 18 (9) , 2269-2279
Abstract
No abstract availableKeywords
Funding Information
- Seventh Framework Programme
- Innovative Medicines Initiative (155005)
- Swiss Institute of Bioinformatics
- GlaxoSmithKline
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (3100A0B-128657, 33CS30-139468, 33CS30-148401, 33CSCO-122661)
- Boehringer Ingelheim
This publication has 34 references indexed in Scilit:
- The SwissLipids knowledgebase for lipid biologyBioinformatics, 2015
- Rare and Common Genetic Events in Type 2 Diabetes: What Should Biologists Know?Cell Metabolism, 2015
- Increased Dihydroceramide/Ceramide Ratio Mediated by Defective Expression of degs1 Impairs Adipocyte Differentiation and FunctionDiabetes, 2014
- Plasma sphingolipids are biomarkers of metabolic syndrome in non-human primates maintained on a Western-style dietInternational Journal of Obesity, 2012
- Fenretinide Prevents Lipid-induced Insulin Resistance by Blocking Ceramide BiosynthesisJournal of Biological Chemistry, 2012
- Ceramides as modulators of cellular and whole-body metabolismJournal of Clinical Investigation, 2011
- Predicting Diabetes: Clinical, Biological, and Genetic ApproachesDiabetes Care, 2008
- Differential effect of inbred mouse strain (C57BL/6, DBA/2, 129T2) on insulin secretory function in response to a high fat dietJournal of Endocrinology, 2005
- Heterogeneous metabolic adaptation of C57BL/6J mice to high-fat dietAmerican Journal of Physiology-Endocrinology and Metabolism, 2002
- Genetic manipulation of insulin signaling, action and secretion in miceEMBO Reports, 2002